Evidence map›Paper›PMID 36587630›Full record

ArticleDrug delivery2023

Progress in the application of hydrogels in immunotherapy of gastrointestinal tumors.

Hao Zheng, Meng Li, Lili Wu, Wenshang Liu, Yu Liu, Jie Gao, Zhengmao Lu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug delivery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Hao ZhengDepartment of General Surgery, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Meng LiDepartment of Dermatology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University, Shanghai, China.
Lili WuChanghai Clinical Research Unit, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Wenshang LiuDepartment of Dermatology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University, Shanghai, China.
Yu LiuDepartment of Gastroenterology, Jinling Hospital, Medical School of Nanjing University, Jiangsu, China.
Jie GaoChanghai Clinical Research Unit, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Zhengmao LuDepartment of General Surgery, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Changhai Hospital · CNShanghai Ninth People's Hospital · CNNanjing General Hospital of Nanjing Military Command · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastrointestinal tumors are the most common cancers with the highest morbidity and mortality worldwide. Surgery accompanied by chemotherapy, radiotherapy and targeted therapy remains the first option for gastrointestinal tumors. However, poor specificity for tumor cells of these postoperative treatments often leads to severe side effects and poor prognosis. Tumor immunotherapy, including checkpoint blockade and tumor vaccines, has developed rapidly in recent years, showing good curative effects and minimal side effects in the treatment of gastrointestinal tumors. National Comprehensive Cancer Network guidelines recommend tumor immunotherapy as part of the treatment of gastrointestinal tumors. However, the heterogeneity of tumor cells, complicacy of the tumor microenvironment and poor tumor immunogenicity hamper the effectiveness of tumor immunotherapy. Hydrogels, defined as three-dimensional, hydrophilic, and water-insoluble polymeric networks, could significantly improve the overall response rate of immunotherapy due to their superior drug loading efficacy, controlled release and drug codelivery ability. In this article, we briefly describe the research progress made in recent years on hydrogel delivery systems in immunotherapy for gastrointestinal tumors and discuss the potential future application prospects and challenges to provide a reference for the clinical application of hydrogels in tumor immunotherapy.

Indexed as

Gastrointestinal NeoplasmsHydrogelsCombined Modality TherapyHumansImmunotherapyTumor MicroenvironmentHydrogelsdrug delivery systemgastrointestinal tumorsHydrogelimmunotherapytumor vaccine

Identifiers

PMID36587630
PMCPMC9809389
OpenAlexW4313441772

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.